Exosomal microRNAs in cancer: Potential biomarkers and immunotherapeutic targets for immune checkpoint molecules

被引:15
作者
Alotaibi, Faizah [1 ]
机构
[1] King Saud bin Abdulaziz Univ Hlth Sci, Coll Sci & Hlth Profess, King Abdullah Int Med Res Ctr, Minist Natl Guard Hlth Affairs, Riyadh, Saudi Arabia
关键词
exosomal miRNA; extracellular vesicles (EVs); cancer; small non-coding RNAs (sncRNAs); biomarker; clinical implication; liquid bioposy; immune checkpoint molecules; ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; CIRCULATING MICRORNAS; OVARIAN-CANCER; TEMOZOLOMIDE RESISTANCE; CLINICAL-SIGNIFICANCE; TRANSFERRIN RECEPTOR; CELL-PROLIFERATION; DIAGNOSTIC MARKER; TUMOR RECURRENCE;
D O I
10.3389/fgene.2023.1052731
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Exosomes are small extracellular vesicles with a lipid bilayer structure secreted from different cell types which can be found in various body fluids including blood, pleural fluid, saliva and urine. They carry different biomolecules including proteins, metabolites, and amino acids such as microRNAs which are small non-coding RNAs that regulate gene expression and promote cell-to-cell communication. One main function of the exosomal miRNAs (exomiRs) is their role in cancer pathogenesis. Alternation in exomiRs expression could indicate disease progression and can regulate cancer growth and facilitate drug response/resistance. It can also influence the tumour microenvironment by controlling important signaling that regulating immune checkpoint molecules leading to activation of T cell anti-tumour immunity. Therefore, they can be used as potential novel cancer biomarkers and innovative immunotherapeutic agents. This review highlights the use of exomiRs as potential reliable biomarkers for cancer diagnosis, treatment response and metastasis. Finally, discuses their potential as immunotherapeutic agents to regulate immune checkpoint molecules and promote T cell anti-tumour immunity.
引用
收藏
页数:14
相关论文
共 149 条
  • [51] Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma
    Iqbal, Javeed
    Shen, Yulei
    Huang, Xin
    Liu, Yanyan
    Wake, Laura
    Liu, Cuiling
    Deffenbacher, Karen
    Lachel, Cynthia M.
    Wang, Chao
    Rohr, Joseph
    Guo, Shuangping
    Smith, Lynette M.
    Wright, George
    Bhagavathi, Sharathkumar
    Dybkaer, Karen
    Fu, Kai
    Greiner, Timothy C.
    Vose, Julie M.
    Jaffe, Elaine
    Rimsza, Lisa
    Rosenwald, Andreas
    Ott, German
    Delabie, Jan
    Campo, Elias
    Braziel, Rita M.
    Cook, James R.
    Tubbs, Raymond R.
    Armitage, James O.
    Weisenburger, Dennis D.
    Staudt, Louis M.
    Gascoyne, Randy D.
    McKeithan, Timothy W.
    Chan, Wing C.
    [J]. BLOOD, 2015, 125 (07) : 1137 - 1145
  • [52] Non-Coding RNAs of Extracellular Vesicles: Key Players in Organ-Specific Metastasis and Clinical Implications
    Jiang, Qian
    Tan, Xiao-Ping
    Zhang, Cai-Hua
    Li, Zhi-Yuan
    Li, Du
    Xu, Yan
    Liu, Yu Xuan
    Wang, Lingzhi
    Ma, Zhaowu
    [J]. CANCERS, 2022, 14 (22)
  • [53] MicroRNA-221 sensitizes chronic myeloid leukemia cells to imatinib by targeting STAT5
    Jiang, Xiaoxiao
    Cheng, Yanhong
    Hu, Chaojie
    Zhang, Aimei
    Ren, Yingli
    Xu, Xiucai
    [J]. LEUKEMIA & LYMPHOMA, 2019, 60 (07) : 1709 - 1720
  • [54] Circulating exosomal MicroRNAs: New non-invasive biomarkers of non-communicable disease
    Jimenez-Avalos, Jorge Armando
    Fernandez-Macias, Juan Carlos
    Gonzalez-Palomo, Ana Karen
    [J]. MOLECULAR BIOLOGY REPORTS, 2021, 48 (01) : 961 - 967
  • [55] Prognostic value of miR-16 expression in childhood acute lymphoblastic leukemia relationships to normal and malignant lymphocyte proliferation
    Kaddar, T.
    Chien, W. W.
    Bertrand, Y.
    Pages, M. P.
    Rouault, J. P.
    Salles, G.
    Ffrench, M.
    Magaud, J. P.
    [J]. LEUKEMIA RESEARCH, 2009, 33 (09) : 1217 - 1223
  • [56] Circulating miRNAs can serve as potential diagnostic biomarkers in chronic myelogenous leukemia patients
    Keramati, Farid
    Jafarian, Arefeh
    Soltani, Adele
    Javandoost, Ehsan
    Mollaei, Mojtaba
    Fallah, Parviz
    [J]. LEUKEMIA RESEARCH REPORTS, 2021, 16
  • [57] Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment
    Kfoury, Youmna
    Baryawno, Ninib
    Severe, Nicolas
    Mei, Shenglin
    Gustafsson, Karin
    Hirz, Taghreed
    Brouse, Thomas
    Scadden, Elizabeth W.
    Igolkina, Anna A.
    Kokkaliaris, Konstantinos
    Choi, Bryan D.
    Barkas, Nikolas
    Randolph, Mark A.
    Shin, John H.
    Saylor, Philip J.
    Scadden, David T.
    Sykes, David B.
    Kharchenko, Peter, V
    [J]. CANCER CELL, 2021, 39 (11) : 1464 - +
  • [58] Expression differences of miR-142-5p between treatment-naive chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance
    Kluemper, Theresa
    Bruckmueller, Henrike
    Diewock, Tobias
    Kaehler, Meike
    Haenisch, Sierk
    Pott, Christiane
    Bruhn, Oliver
    Cascorbi, Ingolf
    [J]. EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2020, 9 (01)
  • [59] miRBase: annotating high confidence microRNAs using deep sequencing data
    Kozomara, Ana
    Griffiths-Jones, Sam
    [J]. NUCLEIC ACIDS RESEARCH, 2014, 42 (D1) : D68 - D73
  • [60] New Concepts in Cancer Biomarkers: Circulating miRNAs in Liquid Biopsies
    Larrea, Erika
    Sole, Carla
    Manterola, Lorea
    Goicoechea, Ibai
    Armesto, Maria
    Arestin, Maria
    Caffarel, Maria M.
    Araujo, Angela M.
    Araiz, Maria
    Fernandez-Mercado, Marta
    Lawrie, Charles H.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (05)